---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-23-003792"
form_type: "8-K"
ticker: "ACHV"
cik: "0000949858"
company_name: "ACHIEVE LIFE SCIENCES, INC."
filed_at: "2023-03-16T23:59:59+00:00"
generated_at: "2026-06-18T01:31:30.430116+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Achieve Life Sciences reports Q4/FY 2022 net loss $42.4M; cash $24.8M; phase 3/2 trial data due Q2 2023

## Summary
- Cash, cash equivalents, and restricted cash totaled $24.8M as of Dec 31, 2022.
- Net loss for FY 2022 was $42.4M; Q4 2022 net loss $11.2M.
- Phase 3 ORCA-3 and Phase 2 ORCA-V1 top-line results expected in Q2 2023.
- Closed $18.9M private placement in Nov 2022 to fund trials and working capital.
- USPTO granted patent for cytisinicline mesylate salt formulation, expiring 2042.

## SEC filing metadata
- accession: 0001564590-23-003792
- form_type: 8-K
- ticker: ACHV
- cik: 0000949858
- company_name: ACHIEVE LIFE SCIENCES, INC.
- filed_at: 2023-03-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/949858/000156459023003792/0001564590-23-003792-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/949858/000156459023003792/achv-8k_20230316.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-23-003792
- JSON: https://secwatch.observer/filing/0001564590-23-003792.json
- Plain text: https://secwatch.observer/filing/0001564590-23-003792.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.